IO Biotech

IO Biotech Dividend per Share

Delisted·Sep 22, 2026

Dividend per Share of IO Biotech (IOBT) as of Nov 20, 2026.

Dividend per Share

0.00USD

Last updated:

Dividend per Share of IO Biotech is 2024 0.00 USD. Dividend per Share of IO Biotech was 2023 0.00 USD. It decreases by % lower compared to the previous year.

The IO Biotech Dividend per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend per Share
Date
Dividend per Share
Jan 1, 2024
0.00 USD
Jan 1, 2025 (e)
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
Jan 1, 2030 (e)
0.00 USD
Jan 1, 2031 (e)
0.00 USD
The IO Biotech Dividend per Share history
YEARDividend per ShareYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

On Eulerpool you can find the complete historical development of Dividend per Share IO Biotech since 2006 – with annual values, charts, and detailed analysis.

Dividend per share is the total dividend payment divided by shares outstanding. It shows how much cash each share receives in dividends.

Dividend per Share's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend per Share's IO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — IO Biotech

All Key Metrics — IO Biotech